Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes

Journal of Hypertension
William B WhiteStuart Kupfer

Abstract

Angiotensin receptor blockers (ARBs) are preferred antihypertensive therapies in patients with type 2 diabetes mellitus (T2DM). Azilsartan medoxomil (AZL-M) is a potent ARB for the treatment of stages 1-2 hypertension. We compared the efficacy, safety, and metabolic effects of AZL-M to both valsartan (VAL) and olmesartan (OLM), separately in patients with impaired fasting glucose (prediabetes mellitus) and T2DM. A pooled analysis of 3821 patients from three separate randomized placebo-controlled trials comparing the effects of AZL-M (40 and 80 mg), OLM (40 mg), VAL (320 mg), and placebo on changes in ambulatory and clinic blood pressure (BP) among patients with hypertension and prediabetes mellitus or T2DM was performed. Two analysis pools were created to facilitate comparisons: Pool A included patients who received placebo, AZL-M or OLM and Pool B included those who received AZL-M or VAL. Within each pool, patients were stratified by glycemic subgroups (normoglycemic, prediabetes mellitus, or T2DM) based on hemoglobin A1c values. Changes from baseline in both 24-h and clinic SBP were the primary efficacy assessments. Baseline 24-h mean SBPs were approximately 145 and 146 mmHg in the prediabetes mellitus and T2DM subgroups, res...Continue Reading

References

May 9, 2007·American Journal of Hypertension·Masaru IwaiMasatsugu Horiuchi
Mar 25, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shiho NakayamaRyuzo Kawamori
Dec 5, 2008·The New England Journal of Medicine·Kenneth JamersonUNKNOWN ACCOMPLISH Trial Investigators
Aug 29, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shin-ichiro MasudaSatoshi Umemura
Dec 3, 2010·The Journal of Pharmacology and Experimental Therapeutics·Mami OjimaHideaki Nagaya
Jan 29, 2011·The Journal of Clinical Hypertension·George L BakrisStuart Kupfer
Oct 12, 2011·Journal of Hypertension·Takashi KajiyaTheodore W Kurtz
Jun 13, 2014·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Daniel Lorber
Feb 11, 2015·JAMA : the Journal of the American Medical Association·Connor A EmdinAnushka Patel

❮ Previous
Next ❯

Citations

Aug 19, 2016·Frontiers in Pharmacology·Georgios GeorgiopoulosDimitrios Tousoulis
Nov 21, 2017·Journal of the American Heart Association·Thomas M MacDonaldUNKNOWN British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm‐based Therapy (PATHWAY)
Feb 23, 2019·Diabetes, Obesity & Metabolism·Piero RuggenentiUNKNOWN VALID Study Organization
Jan 7, 2017·Cardiovascular Diabetology·Alon Grossman, Ehud Grossman
Aug 23, 2019·Current Drug Targets·Khuraijam Dhanachandra Singh, Sadashiva S Karnik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.